1Revenue rose 4.1% to $36.3M, driven by expansion of Nora Pharma sales efforts across Quebec, Ontario, Alberta, and British Columbia.
2Gross profit increased 14.9% to $12.3M and gross margin improved to 33.8%, reflecting a decrease in cost of sales tied to lower professional allowances on sales outside Quebec.
3Net cash used in operating activities improved to -$5.3M (from -$12.5M in FY2024), supported by more streamlined Nora Pharma operations and a significant decrease in the rate of inventory growth.
4Operating income declined to -$6.2M, and net income declined to -$6.0M, consistent with continued investment in the Company’s generic pharmaceutical business model.
5Capital expenditures fell to $174K, reflecting reduced equipment purchases following prior-year infrastructure buildout — a dynamic confirmed in the authoritative financial packet.
6Diluted EPS improved to -$1.44 from -$7.32, though this reflects changes in share count rather than operational improvement, as noted in management commentary.